ClinicalTrials.gg
CompletedNCT00928447Updated Dec 17, 2021Results posted

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

A Phase 2 interventional study of rHuPH20 and Placebo in Dermatitis, Allergic Contact, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Dermatitis, Allergic Contact with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Dermatitis, Allergic Contact · United States.

Enrollment
15th of 22
22 · median 54
Started
2009
with 1 other
Phase 2
4 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
1 of 23
Halozyme Therapeutics

Among the 23 studies in Dermatitis, Allergic Contact with a site in United States, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 4th registered.

Dermatitis, Allergic Contact

52 studies on the registry are indexed under Dermatitis, Allergic Contact; 11 are open to participants now.

Browse Dermatitis, Allergic Contact studies →

Open to participants now

4 of the 23 studies in Dermatitis, Allergic Contact with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Dermatitis, Allergic Contact studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dermatitis, Allergic Contact with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.

Read the detailed description

This study will involve 2 regimens which will run in parallel. Each participant's upper back will be divided into 2 equal spaces for Regimen 1 and 2. Each of the 4 treatment sites in each space will be independently randomized to placebo or rHuPH20 treatment in a 1:1 ratio. Thus, each participant will serve as their own control. Regimen 1 will evaluate the treatment of cutaneous reactions to nickel and Regimen 2 will evaluate the prevention as well as the treatment of cutaneous reactions to nickel. At screening, the nickel sulfate concentration (1%, 2.5%, or 5%) applied to the skin of the upper back with a patch, that will cause no more than a ++ reaction according to the scale of the International Contact Dermatitis Research Group (ICDRG) will be determined. This concentration will be used to elicit cutaneous reactions during the study period.

03

Conditions studied

  • Dermatitis, Allergic Contact

Keywords

  • rHuPH20
  • Recombinant Human hyaluronidase
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females 18-60 years of age. Females of must use a standard and effective means of for the duration of the study.
  • Known contact dermatitis to nickel with a confirmed positive patch-test result to nickel sulfate.
  • Intact normal skin without potentially obscuring tattoos, acne, dermatitis, pigmentation or lesions on the posterior aspect of the torso (back) in the area intended for allergen testing and dose administration.
  • Vital signs (blood pressure [BP], heart rate [HR], temperature, respiratory rate) within normal range or, if out of range, assessed by the Investigator as not and it is mutually agreed by both Investigator and sponsor medical monitor that the participant need not be excluded from the study for this reason.
  • A negative serum or urine pregnancy test (if female of child-bearing potential) within 14 days of initial study drug administration.
  • Participant should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol.
  • Decision-making capacity and willingness and ability to comply with the requirements for full completion of the study.
  • Signed, written Institutional Review Board (IRB)/Ethics Committee (EC)-approved .

Exclusion criteria

Exclusion Criteria:

  • Nickel allergen patch test greater than a ++ reaction.
  • Participants who were treated with chemotherapy agents or systemic within the past 3 months.
  • Use of topical steroids, antihistamines, or used near the site of allergen testing/injection within 14 days.
  • Use of oral antihistamines within 14 days of study conduct.
  • Extensive ongoing outbreaks of contact dermatitis anywhere on the body.
  • Pregnant or women who are breast-feeding.
  • Participants with a current disease state that can affect immune response (for example, flu, cancer, [HIV]).
  • Known allergy to any hyaluronidase or the ingredients in the dose preparation.
  • History of disorder.
  • Participants with any other medical condition that, in the opinion of the investigator, might significantly affect their ability to safely participate in the study or affect the conduct of this study. Examples might include asthma, diabetes, heart disease, epilepsy, cancer, etc.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    rHuPH20

    Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the nickel sulfate concentration (NSC) (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing rHuPH20 (3,000 Units \[U\]) will be administered once daily (QD) for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with drug rHuPH20 (3,000 U) at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing rHuPH20 will be then administered QD for 5 days.

    Drug: rHuPH20

  • Placebo comparator
    Placebo

    Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the NSC (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing placebo will be administered QD for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with placebo at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing placebo will be then administered QD for 5 days.

    Drug: Placebo

Interventions

  • 0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20

  • DrugPlacebo

    0.25 mL ID syringe push bolus injection of placebo control

06

What researchers measure

Primary outcomes

  1. Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1

    Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types. Participants with positive reaction scores (\>= Grade 1) have been reported in this outcome measure.

    Time frame: Day 3 (48 hours post-dose after the patch removal for Regimen 1) up to Day 14

  2. Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 2

    Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types. Participants with positive reaction scores (\>= Grade 1) have been reported in this outcome measure.

    Time frame: Day 3 (48 hours post-dose after the patch removal for Regimen 2) up to Day 14

Secondary outcomes

  1. Percentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 1

    Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types.

    Time frame: Day 3 (48 hours post-dose after the patch removal for Regimen 1)

  2. Percentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 2

    Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types.

    Time frame: Day 3 (48 hours post-dose after the patch removal for Regimen 2)

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAEs were defined as adverse events (AEs) with an onset during or following administration of the first dose of study drug. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. Adverse Events were only monitored/assessed on the whole participant level irrespective of different treatment regimen. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.

    Time frame: Baseline up to Day 14

07

Results

Posted Dec 17, 2021

Participant flow

Participants with a known history of nickel allergy were recruited. At screening, the nickel sulfate concentration (1%, 2.5%, or 5%), applied to the skin of the upper back with a patch, that caused no more than a ++ reaction according to the scale of the International Contact Dermatitis Research Group (ICDRG) was determined. This concentration was used to elicit cutaneous reactions during the study period.

Participant flow — Overall Study
MilestoneOverall Study (rHuPH20 and Placebo)
Started22
Received at least 1 dose of rhuph2021
Received at least 1 dose of placebo21
Completed20
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Investigator's decision1

Outcome measures

PrimaryNumber of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1

Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types. Participants with positive reaction scores (\>= Grade 1) have been reported in this outcome measure.

Time frame:
Day 3 (48 hours post-dose after the patch removal for Regimen 1) up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1
ParticipantsOverall Study (rHuPH20 and Placebo)
rHuPH205
Placebo9
PrimaryNumber of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 2

Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types. Participants with positive reaction scores (\>= Grade 1) have been reported in this outcome measure.

Time frame:
Day 3 (48 hours post-dose after the patch removal for Regimen 2) up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 2
ParticipantsOverall Study (rHuPH20 and Placebo)
rHuPH203
Placebo2
SecondaryPercentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 1

Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types.

Time frame:
Day 3 (48 hours post-dose after the patch removal for Regimen 1)
Reported as:
Number · percentage of participants
Percentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 1
percentage of participantsOverall Study (rHuPH20 and Placebo)
rHuPH2070
Placebo75
SecondaryPercentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 2

Cutaneous reactions at the patch test sites were scored according to the ICDRG scoring scale as Grade 0 (-)= Negative reaction, Grade 1/2 (?)= Doubtful reaction; faint macular erythema only, Grade 1 (1+)= Weak (nonvesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 2 (2+): Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles, Grade 3 (3+): Extreme positive reaction; bullous reaction Grade NA (IR): Irritant reaction of different types.

Time frame:
Day 3 (48 hours post-dose after the patch removal for Regimen 2)
Reported as:
Number · percentage of participants
Percentage of Participants With a >=1 Grade Change in ICDRG Score in at Least One Patch Region After Treatment With rHuPH20 or Placebo: Regimen 2
percentage of participantsOverall Study (rHuPH20 and Placebo)
rHuPH2095
Placebo90
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as adverse events (AEs) with an onset during or following administration of the first dose of study drug. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. Adverse Events were only monitored/assessed on the whole participant level irrespective of different treatment regimen. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.

Time frame:
Baseline up to Day 14
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsOverall Study (rHuPH20 and Placebo)
TEAEs21
SAEs0

Adverse events

Collected over Baseline up to Day 14. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Study (rHuPH20 and Placebo)—0/21 (0%)21/21 (100%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventOverall Study (rHuPH20 and Placebo)
Injection site painGeneral disorders21/21
Injection site pruritusGeneral disorders18/21
HeadacheNervous system disorders10/21
DizzinessNervous system disorders4/21
PruritusSkin and subcutaneous tissue disorders4/21
Injection site discomfortGeneral disorders3/21
Injection site haematomaGeneral disorders3/21
Injection site irritationGeneral disorders3/21
NauseaGastrointestinal disorders2/21
VomitingGastrointestinal disorders2/21

Baseline characteristics

The intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Overall Study (rHuPH20 and Placebo)
Mean39.5 ± 15.34
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study (rHuPH20 and Placebo)
Female22
Male0
08

Study locations

1 site
  • Symbio Phase I Unit, Saint Anthony Memorial Research Center
    Michigan City, Indiana 46360, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2009 to primary completion in Sep 2009, 2 months.

Results were first posted in Dec 2021, 12 years 3 months after primary completion. A results delay was requested in Jun 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2009
First posted
Jun 26, 2009
StartActual
Jun 23, 2009
Primary completionActual
Sep 13, 2009
CompletionActual
Sep 13, 2009
Results delay requested
Jun 28, 2018
Results first posted
Dec 17, 2021
Last update
Dec 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00928447
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Jun 23, 2009
Primary completion
Sep 13, 2009
Completion
Sep 13, 2009
Results posted
Dec 17, 2021
Last update
Dec 17, 2021

Study contacts

Ikeadi M Ndukwu, M.D., MPH
principal investigator · Saint Anthony Memorial Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion